Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals
Paratek’s successful commercialisation platform to advance novel therapies developed organically and through acquisitions
Paratek adds ‘final-mile’ capabilities to AMR efforts
COPENHAGEN, September 21, 2023 – With the closing of the acquisition of Paratek Pharmaceuticals, Inc. (“Paratek”), a commercial-stage biopharmaceutical company focused on the development and commercialisation of novel therapies for life-threatening diseases and other public health threats, Novo Holdings reaches a significant milestone in its efforts to combat antimicrobial resistance (AMR).
